OVERVIEW

Multiple Myeloma (MM): Highlights from the American Society for Clinical Oncology (ASCO) 2018 is organized by ScientiaCME.

Release Date: Jul 19, 2018
Expiration Date: Jul 19, 2020

Accreditation:
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-18-025-H01-P. ACPE Accreditation effective 7/19/18, expires 7/19/20.

Description:
In this online CME self-learning program:
Annual meetings of large, national, professional societies offer an opportunity for healthcare professionals to get a first glimpse at study results that have the potential to impact practice as provide a forum for an exchange of ideas and practices between thought leaders and less distinguished practitioners. ASCO 2018 is no exception. Nevertheless, as with every meeting, many professionals from both the community and health-system settings alike will be unable to attend the conference for a variety of reasons, justifying the creation of educational programming that summarize the major findings presented at the meeting.

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. While MM only makes up about 1% of all cancers, it the most common of the blood cancers with an incidence of a little under 31,000 and an annual mortality rate of just under 13,000. The peak incidence age of MM is at about 70 years of age, and the disease occurs twice as commonly in African Americans as it does in whites.

Objectives:
By the end of the session the participant will be able to:
• Summarize the most impactful findings presented at ASCO 2018 relating to Multiple myeloma and apply them to patient cases, taking into account any relevant barriers to care.
• Additional objectives to be dictated by clinical content